We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Vibalogics, a global contract development and manufacturing organization (CDMO), has initiated Phase I of its planned $150 million investment in a late-phase clinical and commercial virotherapy manufacturing facility near Boston, MA.